Jesse D. Ortendahl

964 total citations
28 papers, 704 citations indexed

About

Jesse D. Ortendahl is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Jesse D. Ortendahl has authored 28 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Jesse D. Ortendahl's work include Cervical Cancer and HPV Research (9 papers), Global Cancer Incidence and Screening (6 papers) and Genital Health and Disease (6 papers). Jesse D. Ortendahl is often cited by papers focused on Cervical Cancer and HPV Research (9 papers), Global Cancer Incidence and Screening (6 papers) and Genital Health and Disease (6 papers). Jesse D. Ortendahl collaborates with scholars based in United States, Spain and Peru. Jesse D. Ortendahl's co-authors include Sue J. Goldie, Meredith O’Shea, Natasha K. Stout, Jeremy D. Goldhaber‐Fiebert, Stephen Sy, Michael S. Broder, Tanya G. K. Bentley, Jorge Arellano, Andrea Singer and J. Vanderpuye-Orgle and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Allergy and Clinical Immunology and British Journal of Cancer.

In The Last Decade

Jesse D. Ortendahl

26 papers receiving 679 citations

Peers

Jesse D. Ortendahl
Tim Bancroft United States
Anna Finnane Australia
Aneela Hussain Saudi Arabia
Jayne Smith‐Palmer Switzerland
Paolo Sciattella Italy
D Barzilai United States
Liisa Lyon United States
Mary Anderson United States
J Clarke United States
Caroline G. Tai United States
Tim Bancroft United States
Jesse D. Ortendahl
Citations per year, relative to Jesse D. Ortendahl Jesse D. Ortendahl (= 1×) peers Tim Bancroft

Countries citing papers authored by Jesse D. Ortendahl

Since Specialization
Citations

This map shows the geographic impact of Jesse D. Ortendahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse D. Ortendahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse D. Ortendahl more than expected).

Fields of papers citing papers by Jesse D. Ortendahl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse D. Ortendahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse D. Ortendahl. The network helps show where Jesse D. Ortendahl may publish in the future.

Co-authorship network of co-authors of Jesse D. Ortendahl

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse D. Ortendahl. A scholar is included among the top collaborators of Jesse D. Ortendahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse D. Ortendahl. Jesse D. Ortendahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ortendahl, Jesse D., et al.. (2020). PCN2 PROJECTED LIFETIME CLINICAL VALUE OF A MULTICANCER EARLY DETECTION TEST. Value in Health. 23. S22–S22. 1 indexed citations
2.
Ortendahl, Jesse D., et al.. (2018). Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend?. Clinical Cardiology. 42(1). 47–55. 8 indexed citations
3.
Amin, Alpesh, et al.. (2018). Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. Current Medical Research and Opinion. 34(3). 559–566. 1 indexed citations
4.
Ortendahl, Jesse D., Sonia Pulgar, Beloo Mirakhur, et al.. (2017). Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. ClinicoEconomics and Outcomes Research. Volume 9. 495–503. 8 indexed citations
5.
Ortendahl, Jesse D., et al.. (2017). A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies. Journal of Medical Economics. 20(7). 767–775. 1 indexed citations
6.
Martínez‐López, Joaquín, Tanya G. K. Bentley, Michael J. Cangelosi, et al.. (2016). Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer. Journal of Gastrointestinal Cancer. 48(1). 58–65. 16 indexed citations
7.
Cogle, Christopher R., Jesse D. Ortendahl, Tanya G. K. Bentley, et al.. (2015). Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Review of Pharmacoeconomics & Outcomes Research. 16(2). 275–284. 3 indexed citations
8.
Citrome, Leslie, Siddhesh Kamat, Christophe Sapin, et al.. (2014). Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics. 17(8). 567–576. 20 indexed citations
9.
Ortendahl, Jesse D., et al.. (2014). Cost-Effectiveness of Cetuximab as First-Line Treatment for Metastatic Colorectal Cancer in the United States. Value in Health. 17(3). A86–A86. 4 indexed citations
10.
Cangelosi, Michael J., et al.. (2014). Cost–effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Review of Pharmacoeconomics & Outcomes Research. 15(2). 357–364. 24 indexed citations
11.
Bentley, Tanya G. K., Brock E. Schroeder, Catherine A. Schnabel, et al.. (2014). Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer. Journal of Medical Economics. 17(8). 527–537. 3 indexed citations
12.
13.
Burger, Emily A., et al.. (2012). Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. British Journal of Cancer. 106(9). 1571–1578. 63 indexed citations
14.
Goldie, Sue J., et al.. (2012). Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Revista Panamericana de Salud Pública. 32(6). 426–434. 4 indexed citations
15.
Campos, Nicole G., Jane J. Kim, Philip E. Castle, et al.. (2011). Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. International Journal of Cancer. 130(11). 2672–2684. 68 indexed citations
16.
Sharma, Monisha, et al.. (2011). Cost‐effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG An International Journal of Obstetrics & Gynaecology. 119(2). 166–176. 41 indexed citations
17.
Díaz, Mireia, Sílvia de Sanjosé, Jesse D. Ortendahl, et al.. (2010). Cost-effectiveness of human papillomavirus vaccination and screening in Spain. European Journal of Cancer. 46(16). 2973–2985. 34 indexed citations
18.
Levin, Carol, John W. Sellors, Jufang Shi, et al.. (2010). Cost‐effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high‐risk region of China. International Journal of Cancer. 127(6). 1404–1411. 51 indexed citations
19.
Stout, Natasha K., Jeremy D. Goldhaber‐Fiebert, Jesse D. Ortendahl, & Sue J. Goldie. (2008). Trade-offs in Cervical Cancer Prevention. Archives of Internal Medicine. 168(17). 1881–1881. 41 indexed citations
20.
Goldhaber‐Fiebert, Jeremy D., Natasha K. Stout, Jesse D. Ortendahl, et al.. (2007). Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Population Health Metrics. 5(1). 11–11. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Bancroft Breakdown of academic impact, for papers by Anna Finnane Breakdown of academic impact, for papers by Aneela Hussain Breakdown of academic impact, for papers by Jayne Smith‐Palmer Breakdown of academic impact, for papers by Paolo Sciattella Breakdown of academic impact, for papers by D Barzilai Breakdown of academic impact, for papers by Liisa Lyon Breakdown of academic impact, for papers by Mary Anderson Breakdown of academic impact, for papers by J Clarke Breakdown of academic impact, for papers by Caroline G. Tai
Rankless by CCL
2026